Description
Created On: 2020-07-15
Record Count: 7
Primary Industries
- Drugs
- Vaccine
- Cancer
- Disease
- Therapeutic
- DNA
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 280952
For the Research Licenses, Licensor grants a world-wide, non-exclusive license, with the right to sublicense, under the Licensed Patents and Know-How, to use and import Licensed Adjuvant solely to conduct research for, or in respect of, the development of Products for use in the Field of Use for the Term.
Licensor grants the right to sublicense the rights granted herein.
For the Trademark License, Licensor grants a worldwide, royalty-free, nontransferable, non-exclusive license, during the term, to use and reproduce the Powered by Corixa trademark in the course of distributing, promoting and selling the Products solely for use within the Field of Use in the Territory.
Product means any pharmaceutical composition, comprising the Licensees Antigen and Licensed Adjuvant as an ingredient or component.
Licensees Antigen, BLP25 MUCl antigen, as such antigen may be improved, enhanced, or otherwise modified, as well as any other antigens that incorporate MUC 1.
IPSCIO Record ID: 230762
This agreement also includes a non-exclusive and exclusive grant back from Licensee to Licensor.
L523S Vaccine shall mean a Vaccine which contains all or a portion of the L523S Antigen.
Licensor Patents shall mean all patents and patent applications; that cover patentable inventions or discoveries made by Licensor solely or together with a Third Party in the course of the Initial Agreement Activities, or, that cover patentable inventions or discoveries that generically or specifically claim all or any part of any L523S, Vaccine, a process for manufacturing any L523S: Vaccine, intermediates used in such process or a use of any L523S Vaccine, and which are now or become owned and/or controlled by Licensor and/or under which Licensor otherwise has, now or in the future, the right to grant licenses. Included within the definition of Licensor Patents are any continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, improvement patents and/or foreign counterparts thereof. In no event shall Licensor Patents be deemed to include the Licensee Patents.
Licensee Products shall mean all Licensee Antibody Products and Licensee Vaccine Product.
L523S is an RNA-binding protein as a potential therapeutic target for lung cancer.
IPSCIO Record ID: 249713
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.
In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
• Any and all Antigens expressed in Lung Cancer
The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.
Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.
IPSCIO Record ID: 232446
This agreement also includes a non-exclusive grant back from Licensee to Licensor.
Licensor Adjuvant Know-How shall mean any technical information, materials or know-how exclusively related to any adjuvant owned or controlled by Licensor, including without limitation the protein Leishmania Elongation Initiation Factor, known as LeIF, MPL, or any synthetic adjuvant.
Antigen(s) shall mean the antigens and/or protein and/or other physical form based on such antigens, such as peptides and/or nucleic acids(s) (DNA, RNA) delivered in any form, including recombinant vectors, to the extent such antigens are covered by one or more Valid Claim(s) of any of the Licensor Patents.
IPSCIO Record ID: 233439
Vaccines, including, without limitation, transfer of Vaccines to third parties for preclinical testing, toxicology, or clinical trials, without the prior written approval of Berna, such approval not to be unreasonably withheld. The license granted is specific to the Disease Field.
Licensor grants the right to sublicense the right to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories under the adr-HBsAg Technology in the Disease Field.
Therapeutic Vaccine shall mean a therapeutic hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilises additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.
Prophylactic Vaccine shall mean a prophylactic Hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilizes additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.
IPSCIO Record ID: 301043
IPSCIO Record ID: 275977
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants the Licensee of Denmark a worldwide, nonexclusive, non sublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensor under the Research and Development Program.
Licensor grants a worldwide, non-exclusive and nontransferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor. Patent Rights and the Joint Patent Rights, to make, have made, use, sell, offer for sale and import Licensee-Combined Vaccines or the Program Vaccines.
